Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Grifols SA       ES0171996012

GRIFOLS SA
Mes dernières consult.
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (EUR)
Sales 2018 4 435 M
EBIT 2018 1 120 M
Net income 2018 659 M
Debt 2018 4 868 M
Yield 2018 1,53%
Sales 2019 4 643 M
EBIT 2019 1 246 M
Net income 2019 746 M
Debt 2019 4 546 M
Yield 2019 1,73%
P/E ratio 2018 24,89
P/E ratio 2019 22,37
EV / Sales2018 4,64x
EV / Sales2019 4,36x
Capitalization 15 700 M
More Financials
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through the following segments:... 
Sector
Pharmaceuticals
Calendar
05/25 | 12:00pmShareholder meeting
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS SA
05/10GRIFOLS : Patent Issued for Purification of Cell Culture Derived Alpha1 Protease..
AQ
05/09GRIFOLS : increases its net profit by 7% to Euros 143 million and delivers signi..
AQ
05/04GRIFOLS : announces Q1 2018 financial results
AQ
05/03GRIFOLS : 1st quarter results
CO
04/20GRIFOLS : donates over 25 million international units of blood clotting factor i..
AQ
04/17GRIFOLS : Donates 25M-Plus Units in 2017, Same Planned for 2018
AQ
04/10GRIFOLS : and IrsiCaixa join forces to promote biomedical research on HIV and as..
AQ
04/10GRIFOLS : Catoctin group proposes putting Thurmont on the map with little librar..
AQ
04/06ARADIGM : Linhaliq under EMA review for lung infection
AQ
03/27GRIFOLS : concludes the experimental phase of AMBAR, a clinical trial on Alzheim..
AQ
More news
Sector news : Biopharmaceuticals
02:00pSUN PHARMACEUTICAL INDUSTRIES : Pharma Consolidated Net Profit Rises 7%
DJ
12:49pALEXION : Wilson Therapeutics Holders Accept Offer
DJ
11:08aBayer cuts Monsanto synergy target by $300 million due to divestments
RE
09:29aAstraZeneca cancer drug hits second goal by extending survival
RE
08:48aPFIZER : Plans to Pay $24 Million To Settle Probe Over Medicare -- WSJ
DJ
More sector news : Biopharmaceuticals
News from SeekingAlpha
2016Midday Gainers / Losers 
2015Tracking John Paulson's Paulson & Company Portfolio - Q3 2015 Update 
2015TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial 
2015Tracking John Paulson's Paulson & Company Portfolio - Q2 2015 Update 
2015Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update 
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 24
Average target price 25,3 €
Spread / Average Target 0,89%
EPS Revisions
Managers
NameTitle
Raimon Grifols Roura Joint Chief Executive Officer & Director
Victor Grifols Deu Joint Chief Executive Officer & Executive Director
Víctor Grifols Roura Non-Executive Chairman
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Vicente Blanquer Torre Vice President-Quality, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS SA18 381
CSL LIMITED0.00%62 614
BIOGEN-10.72%60 013
ALEXION PHARMACEUTICALS-1.22%26 064
GRIFOLS3.05%18 381
BIOMARIN PHARMACEUTICAL-0.80%15 600